Short-term improved vascular function after consuming red raspberries

A recent randomized controlled trial, published in the Archives of Biochemistry and Biophysics, provides insights on the promising outcomes of short-term improvements in blood vessel function among healthy males who consumed dietary achievable amounts of red raspberries. The subjects - ten healthy males aged 18 to 35 - consumed drinks prepared with 200g and 400g of frozen raspberries containing 201 or 403 mg of total polyphenols, or a matched control drink in terms of macro and micronutrient content, color, and taste.

Researchers investigated the vascular effects of the subjects at baseline, 2 hours-post consumption and 24 hours-post consumption of the raspberry and control test drinks. Participants consuming the red raspberry drink showed improved flow-mediated dilation (FMD), an established biomarker of cardiovascular disease risk. FMD increased significantly at 2 hours post-consumption of the raspberry drink when compared with the change in FMD due to the control drink, and this maintained at 24 hours after consumption.

At 2 hours post-consumption of both raspberry drinks, ellagic acid, found in plasma and urine correlated with FMD. At 24 hours post-consumption of the 200g raspberry drink, urolithin-A-3-glucuronide and urolithin-A-sulfate correlated with FMD. No significant differences were found between FMD improvements after consumption of the 200g and 400g raspberry drinks.

"The research study suggests that ellagitannins, a type of natural compounds present in red raspberries, may play a role in driving the positive effects seen on blood vessel function in the study's participants," commented Dr. Ana Rodriguez-Mateos, principal investigator and senior author of the study from the Department of Nutritional Sciences, Faculty of Life Sciences and Medicine of King's College London.

"We're excited about these findings and what they may potentially add to the growing list of benefits from consuming red raspberries," commented Tom Krugman, Executive Director of the National Processed Raspberry Council (NPRC).

Further studies will need to show whether these results translate into long-term health benefits in the general population by looking at larger study groups over longer timeframes.

Istas G, Feliciano RP, Weber T, Garcia-Villalba R, Tomas-Barberan F, Heiss C, Rodriguez-Mateos A.
Plasma urolithin metabolites correlate with improvements in endothelial function after red raspberry consumption: A double-blind randomized controlled trial.
Arch Biochem Biophys. 2018 Aug 1;651:43-51. doi: 10.1016/j.abb.2018.05.016.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...

Pfizer terminates domagrozumab (PF-06252616) clini…

Pfizer Inc. (NYSE: PFE) announced that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrop...